Samsara BioCapital’s Jasper Therapeutics JSPR Stock Holding History

Samsara BioCapital’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-584,642	Closed	-$12.5M	–	42
2024 Q4	$12.5M	Hold	584,642	–	–	1.72%	11
2024 Q3	$11M	Buy	584,642 +59,642	+11%	+$1.19M	2.11%	14
2024 Q2	$11.9M	Hold	525,000	–	–	2.49%	10
2024 Q1	$15.4M	Buy	+525,000	New	+$9.33M	2.38%	11

Other funds holding JSPR

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Samsara BioCapital's JSPR Position: Q1 2025 in Review

Samsara BioCapital sold out of Jasper Therapeutics (JSPR) in Q1 2025, closing a stake of 584,642 shares — an estimated $12.5M sold.

Samsara BioCapital first reported a position in JSPR in Q1 2024 and held it in 4 quarters. The position peaked at $15.4M in Q1 2024. 68 funds tracked by Wall St. Rank hold JSPR as of Q1 2025.

Samsara BioCapital reported no remaining Jasper Therapeutics position as of Q1 2025 after selling out during the quarter.
Samsara BioCapital sold 584,642 Jasper Therapeutics shares in Q1 2025, an estimated $12.5M.
Samsara BioCapital first reported a position in Jasper Therapeutics in Q1 2024 and held it in 4 quarters.
Samsara BioCapital's Jasper Therapeutics position peaked at $15.4M in Q1 2024.
68 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2025.

Based on Samsara BioCapital's 13F filing for Q1 2025, filed 15 May 2025.